A reduced N20-P25 amplitude may serve as an independent and objective electrophysiological biomarker for the early prediction of PSH. In combination with younger age and male patient, it contributes to the identification of high-risk populations and offers valuable guidance for clinical management.
Liu et al. (Wed,) studied this question.